Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...
Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...
Abemaciclib improved progression-free survival at 6 months in meningiomas with NF2 or CDK pathway alterations, achieving a 58 ...
In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable ...
MedPage Today on MSN
Regimen improves PFS in highly mutated metastatic colorectal cancer
But is the combination a "viable alternative" to nivolumab and ipilimumab?
Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...
– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – – Although median overall ...
CHICAGO — First-line NALIRIFOX significantly extended in OS and PFS vs. gemcitabine and nab-paclitaxel among patients with treatment-naive metastatic pancreatic ductal adenocarcinoma, according to a ...
Niraparib monotherapy in HRd EOC patients showed longer rwPFS and rwTTNT, particularly in BRCA-mutated tumors, compared to the overall population. The study used Flatiron Health data, focusing on US ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results